Burkitt Lymphoma
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (1) | CD20 + | Burkitt Lymphoma | Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine | |
| FDA (1) | t(KMT2A;v) | Burkitt Lymphoma | Revumenib | |
| EMA (1) | CD20 + | Burkitt Lymphoma | Corticosteroid, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Methotrexate, Rituximab, Vincristine | |
| FDA (1) | NPM1 p.W288Cfs*12 | Burkitt Lymphoma | Revumenib |